The FDA announced on Jan. 31, 2023, that Biocon Pharma Inc. voluntarily recalled Posaconazole Delayed-Release Tablets due to failed impurity specifications. The recall affects 3,665 bottles distributed nationwide.
How to tell if you have it
- Brand: Biocon Pharma
- Product: Posaconazole Delayed-Release Tablets, 100 mg, 60-count bottle
- NDC: 70377-038-11
- Lot codes: BF21003163 (Exp. Sep-2023), BF21003246 (Exp. Sep-2023), BF21003161 (Exp. Sep-2023), BF21004742 (Exp. Dec-2023), BF22003359 (Exp. Sep-2025)
- Quantity: 3,665 bottles
- Distribution: Nationwide in the USA
The hazard
According to the FDA, the recalled tablets contain high out-of-specification degradation results. The agency classified this as a Class II recall.
Context
GovInfoNow's records show Biocon Pharma Inc. has one other recall on record since March 17, 2025, for Atorvastatin 40mg Tablets due to failed dissolution specifications. Other recent recalls of similar products include Unichem Bisoprolol/Hydrochlorothiazide Tablets Recall (Jan. 21, 2026), Sagent Busulfan Injection Recall (May 4, 2026), and Appco Pharma Recalls Prazosin Capsules Due to Nitrosamine Impurity Risk (March 27, 2026).